Cheung R, Lewanczuk R Z, Rodger N W, Huff M W, Oddou-Stock P, Botteri F, Pecher E, Muirhead N
School of Physical Sciences, Chemistry and Biochemistry, University of Windsor, Ontario, Canada.
Int J Clin Pract. 1999 Dec;53(8):584-92.
The study compared valsartan 80 mg or 160 mg o.d. with captopril 25 mg t.i.d. or placebo on plasma lipids in normotensive and treated hypertensive patients with type II diabetes and microalbuminuria. One hundred and twenty-two adult outpatients were randomised to receive either valsartan 80 mg or 160 mg, captopril 25 mg or placebo for 360 days. Changes from baseline to endpoint in plasma lipid parameters were measured. The primary criterion for tolerability was the incidence of adverse events. All treatment groups showed minor changes in lipid parameters. Triglyceride increased by 2.7% (valsartan 160 mg) to 9.1% (placebo). Total cholesterol decreased under valsartan 80 mg, while other groups showed increases of up to 0.031 mmol/l. Decreases in total cholesterol (p = 0.018), apolipoprotein B (p = 0.042) and apolipoprotein A1 (p = 0.025), were significant for the comparison of 80 mg valsartan and captopril. Valsartan 80 mg or 160 mg o.d. does not cause deleterious changes in the diabetic lipid profile and, unlike captopril, is not associated with dry cough.
该研究比较了缬沙坦80毫克或160毫克每日一次与卡托普利25毫克每日三次或安慰剂对血压正常以及接受治疗的II型糖尿病合并微量白蛋白尿高血压患者血脂的影响。122名成年门诊患者被随机分配接受缬沙坦80毫克或160毫克、卡托普利25毫克或安慰剂治疗360天。测量了从基线到终点血脂参数的变化。耐受性的主要标准是不良事件的发生率。所有治疗组的血脂参数均有轻微变化。甘油三酯升高了2.7%（缬沙坦160毫克组）至9.1%（安慰剂组）。缬沙坦80毫克组总胆固醇降低，而其他组总胆固醇升高高达0.031毫摩尔/升。缬沙坦80毫克与卡托普利比较，总胆固醇（p = 0.018）、载脂蛋白B（p = 0.042）和载脂蛋白A1（p = 0.025）的降低具有显著性。缬沙坦80毫克或160毫克每日一次不会导致糖尿病患者血脂谱出现有害变化，并且与卡托普利不同，不会引起干咳。
